Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.
Pancreatic Cancer
DRUG: Placebo|DRUG: Caprelsa (vandetanib)
Overall survival, To assess whether survival times for patients receiving gemcitabine plus vandetanib are longer than for those patients receiving gemcitabine alone as first line treatment for advanced pancreatic cancer, Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation
Progression-free survival time, Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation|Objective response rate, Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation|Disease control rate, Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation|Number and types of adverse events, Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation|Patient pain assessment, Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation
ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.